- Company
- Expansion of NIP needed for 20-valent pneumococcal vaccine
- by Whang, byung-woo Jan 8, 2025 05:53am
- "Invasive pneumococcal disease remains the most common invasive infection and poses a significant burden. Pneumococcal diseases, such as pneumonia or ear infection, pose significant burden. The new vaccine must cover conventional serotypes as well as newly introduced serotypes to manage the invasive pneumococcal infection and expect an additiona
- Opinion
- [Reporter's View] Pharma bio stocks shunned for good reason
- by Kim, Jin-Gu Jan 8, 2025 05:53am
- The sarcastic comment that “escaping from the KOSPI (Korean stock market) is a matter of intelligence” has become a trend for some time. Although the so-called “Korea discount” is not new, the distrust of the Korean stock market among individual investors has been rising recently. Pharmaceutical, biotech, and healthcare stocks are no
- Company
- New drug 'Truqap' for HER2- breast cancer Rx available
- by Son, Hyung Min Jan 8, 2025 05:53am
- 'Truqap,' an oral anticancer drug that targets AKT gene mutation, is now available for prescription at general hospitals. According to industry sources, AstraZeneca Korea's Truqap (capivasertib), a treatment for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, has passed t
- Company
- Twice yearly HIV drug 'lenacapavir' receives ODD
- by Eo, Yun-Ho Jan 7, 2025 06:05am
- Twice yearly injectable 'lenacapavir' for HIV prevention has been designated as an orphan drug in South Korea. The Ministry of Food and Drug Safety (MFDS) recently announced this through the new year's first orphan drug designation notification. The drug is indicated 'In combination with other antiretroviral therapy, for treatment of p
- Policy
- Dong-A ST first to pay the raised new drug approval fee?
- by Lee, Hye-Kyung Jan 7, 2025 06:05am
- With the new drug approval fee raised to KRW 410 million on Jan. 1 this year, the industry is eyeing whether Dong-A ST will become the first to apply for marketing authorization and pay the raised new drug approval fee. According to industry sources on the 7th, Dong-A ST applied for a prior consultation before applying for marketing authoriza
- Company
- AstraZeneca Korea recertified Innovative Pharma Company
- by Whang, byung-woo Jan 7, 2025 06:05am
- AstraZeneca Korea announced today that it has successfully extended its certification as a 2024 Innovative Pharmaceutical Company by the Ministry of Health and Welfare. This marks the third consecutive recertification since the company was first certified in 2018, and recognizes the company's steady R&D investments and achievements made t
- Product
- Will doctor-pharmacist conflict reignite?
- by Kim JiEun Jan 7, 2025 06:05am
- With candidate Joo Soo-ho, who advocates for the selective dispensing of drugs, advancing to the runoff election for the new president of the Korean Medical Association, a potential conflict between the medical community and the pharmaceutical association is expected. In the 43rd presidential election of the Korean Medical Association, wh
- Opinion
- [Reporter's View] Switching of drugs reimbursable
- by Eo, Yun-Ho Jan 6, 2025 05:57am
- When a patient chooses one medication and switches to another, reimbursement does not cover the latter. Non-reimbursable drug switching has been a long-standing issue in South Korea. At the end of last year, a long-standing issue in one field was resolved. The Ministry of Health and Welfare (MOHW) granted approval for drug switching for p
- Policy
- Zolgensma shows 94% effect during post-evaluations
- by Lee, Tak-Sun Jan 6, 2025 05:56am
- The spinal muscular atrophy (SMA) treatment Zolgensma (onasemnogene abeparvovec) showed promising results suited to its high price. The use of the once-daily, one-shot treatment, which has an insurance cap set at KRW 2, requires a post-marketing evaluation to measure its cost-effectiveness. According to industry sources on the 5th, Z
- Company
- 1st RSV preventive inj 'Beyfortus' can be prescribed
- by Eo, Yun-Ho Jan 6, 2025 05:56am
- The first injectable antibody drug approved in South Korea to prevent respiratory syncytial virus (RSV), 'Beyfortus,' is now available for prescription at general hospitals. According to industry sources, Sanofi Korea's Beyfortus (nirsevimab) has passed the drug committees (DC) of medical centers, including Seoul National University Hospi
